ALLERGAN AUSTRALIA PTY LIMITED

New Kids on the Block highlights September's best product launches, including SkinMedica's HA⁵ Hydra Collagen Replenish + Restore Hydrator, Garage Clothing's loungewear, Caliray's Blurry Blush, Tecovas' Dakota boots, Nars' Explicit Lipstick, Quince's cashmere sweaters, Beachwaver's Heatless Curl Kit, Heat Healer's lymphatic leggings, and Typology Paris' Fortifying Brow Gel.

Greenwalt, a pharmaceutical market analyst, discusses his 25-year career, spanning sales, marketing, and market access, and his current role leading IQVIA's market access team. He highlights the challenges of product access in the U.S., including margin compression and the Inflation Reduction Act, and the complexities of biosimilar market success. Greenwalt also touches on the evolving role of GLP-1s in obesity treatment and the potential impact of the Inflation Reduction Act on pharmaceutical innovation and pricing.

Establishment Labs received FDA approval for Motiva breast implants, the first new U.S. approval since 2013. Motiva's surface enhances biocompatibility, with low inflammation and rupture rates. The company has delivered nearly four million implants globally and forecasts $174-$184 million in global revenue for 2024.

QR678 appoints Sridhar Ranganathan to its Board of Advisors, leveraging his expertise in biotechnology, healthcare, and aesthetics from his tenure at Allergan, where he scaled up Botox and transformed it into a leading product.

CDSCO revoked Entod Pharmaceuticals' authorization to market PresVu eye drops, citing false claims and safety concerns around pilocarpine, the active ingredient.

Semaglutide injections reduced overall, cardiovascular, and infection-related deaths by 19%, 15%, and 23% respectively in a study of 17,000 obese and overweight patients with heart disease.

JFK, PL, CCW, TYW, XZ, PMW, SL, LB, ZH, SF, KWC, KR, and SS have various consulting roles, advisory board memberships, or research support from numerous pharmaceutical and medical technology companies.